These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11357647)

  • 1. Limiting dilution assay.
    Frisan T; Levitsky V; Masucci M
    Methods Mol Biol; 2001; 174():213-6. PubMed ID: 11357647
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of antigen and fine peptide specificity of EBV-specific CTLs.
    Levitsky V; Frisan T; Masucci M
    Methods Mol Biol; 2001; 174():209-11. PubMed ID: 11357646
    [No Abstract]   [Full Text] [Related]  

  • 3. Generation of polyclonal EBV-specific CTL cultures and clones.
    Levitsky V; Frisan T; Masucci M
    Methods Mol Biol; 2001; 174():203-8. PubMed ID: 11357645
    [No Abstract]   [Full Text] [Related]  

  • 4. The immunology of Epstein-Barr virus infection.
    Moss DJ; Burrows SR; Silins SL; Misko I; Khanna R
    Philos Trans R Soc Lond B Biol Sci; 2001 Apr; 356(1408):475-88. PubMed ID: 11313006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
    Delecluse HJ; Feederle R; Behrends U; Mautner J
    Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Purification and application of viral capsid antigen of Epstein-Barr virus].
    Zhou W; Gu S
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):252-5. PubMed ID: 15617341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell memory: lessons from Epstein-Barr virus infection in man.
    Rickinson AB; Callan MF; Annels NE
    Philos Trans R Soc Lond B Biol Sci; 2000 Mar; 355(1395):391-400. PubMed ID: 10794060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic evaluation of a new panel of assays for Epstein-Barr virus serology.
    Radtke M; Gärtner B; Franke D
    Clin Lab; 2007; 53(3-4):149-50. PubMed ID: 17447650
    [No Abstract]   [Full Text] [Related]  

  • 9. New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire.
    D'Orsogna LJ; Amir AL; Zoet YM; van der Meer-Prins PM; van der Slik AR; Kester MG; Heemskerk MH; Doxiadis II; Roelen DL; Claas FH
    Tissue Antigens; 2009 Oct; 74(4):290-7. PubMed ID: 19624615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression assay.
    Frisan T; Levitsky V; Masucci M
    Methods Mol Biol; 2001; 174():199-201. PubMed ID: 11357644
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy with virus-specific cytotoxic T lymphocytes after organ transplantation.
    Lucas KG; Sun Q
    Pediatr Transplant; 2006 Mar; 10(2):142-4. PubMed ID: 16573596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma.
    Masmoudi A; Toumi N; Khanfir A; Kallel-Slimi L; Daoud J; Karray H; Frikha M
    Cancer Treat Rev; 2007 Oct; 33(6):499-505. PubMed ID: 17544585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recombinant AAV-LMP-induced LMP specific cytotoxic response to autologous lymphoblastoid cell lines tranformed by Epstein-Barr virus].
    Zhao F; Liu H; Zhou L; Cai W; Du B; Ye S; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):247-51. PubMed ID: 15617340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies for detecting EBV latent proteins.
    Rowe M; Mehl A
    Methods Mol Biol; 2001; 174():219-27. PubMed ID: 11357648
    [No Abstract]   [Full Text] [Related]  

  • 18. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Epstein-Barr virus antibodies, anti-VCA avidity by immunofluorescence and immunoblot assays for assessment of Epstein-Barr virus immunologic state.
    Sener AG; Afsar I; Pinar E
    J Virol Methods; 2009 Aug; 159(2):300-2. PubMed ID: 19406156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immunofluorescence assay and multiplexed microparticle-based immunoassay for detecting Epstein-Barr virus viral capsid antigen antibodies.
    Zeytinoglu A; Altuglu I; Karatas E; Yazan Sertoz R
    J Virol Methods; 2008 Mar; 148(1-2):300-2. PubMed ID: 18215427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.